On September 8, 2022 GlyTherix Ltd reported that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland (Press release, Glytherix, SEP 8, 2022, View Source [SID1234619225]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry.
GlyTherix CEO Brad Walsh stated: "GlyTherix is delighted to be a key industry partner in this project. This project strengthens our long-standing collaboration with Professor Kris Thurecht’s group at The University of Queensland and the Australian Institute for Bioengineering and Nanotechnology (AIBN). The Hub will allow GlyTherix and UQ to accelerate the development of novel imaging and therapeutic versions of GlyTherix’s antibody Miltuximab for the diagnosis and treatment of a range of solid cancers, including prostate, pancreatic, glioblastoma, bladder and non-small cell lung cancer. This grant will further strengthen Australia’s capabilities in this exciting area of novel targeted radiopharmaceutical products and help bring new therapies to Australian patients."
AMTAR Research Hub Director, Professor Kristofer Thurecht from The University of Queensland added, "We are pleased to be working with GlyTherix and other industry and academic partners on this exciting and innovative research program. A key member of a high calibre project team, GlyTherix’s deep expertise in biologics as radiopharmaceuticals will help drive clinical and commercial translation, and advance the technologies required to ensure long-term production capability in Australia."